Skip to content

Pioneering New Approaches to Rare Diseases

We are dedicated to identifying and developing novel treatments for diseases that affect fewer than 200,000 individuals in the United States. In addition to our lead products, TARPEYO® (budesonide) delayed release capsules and Kinpeygo®, Calliditas also has a pipeline to address a variety of diseases, including primary biliary cholangitis and squamous cell carcinoma of the head and neck.

OUR PIPELINE

Preclinical
Phase 1
Phase 2
Phase 3
Marketed
Rights
Commercial Region
NEFECON*
IgAN
United States
ROW ex partnered
IgAN
Europe, UK, Switzerland
IgAN
China, Hong Kong, Macau, Taiwan, Singapore, South Korea
IgAN
Japan
Setanaxib
PBC
Global
SCCHN
Global
IPF
Global
Alport
Global
Commercial:
Ongoing Trial:
Planned Trial:
Investigator Led Trial:

* Approved in the US under the tradename TARPEYO® to reduce the loss of kidney function in adults with primary IgAN at risk for disease progression, and granted condi-
tional marketing authorization in the EEA and UK under the tradename Kinpeygo® for the treatment of primary IgAN in adults at risk of rapid disease progression with a urine
protein-to-creatinine ratio (UPCR) ≥1.5 g/gram, and granted conditional approval in China under the tradename Nefecon®.

SETANAXIB: TARGETING PRIMARY BILIARY CHOLANGITIS WITH NOX ENZYME INHIBITION

In a Phase 2a trial, patients with primary biliary cholangitis (PBC) experienced statistically significant improvements in fatigue and liver stiffness.

At this time, Calliditas Therapeutics does not provide access to investigational products outside of clinical trials. You and your health care provider can learn more about our clinical trials by visiting www.clinicaltrials.gov and searching for “Calliditas Therapeutics”.